One Stop Shop for All Your Market Research Reports

Global (United States, European Union and China) G-CSF and G-CSF Biosimilars Market Research Report 2019-2025

G-CSF, which is also known as filgrastim, is a growth factor used to aid the recovery of bone marrow after chemotherapy treatment for cancer, especially in patients with neutropenia (low white blood cell count in the blood), which causes reduced resistance to infections. It can also be used to stimulate mobilization of haematopoietic stem cells for collection and transplantation. In 2019, the market size of G-CSF and G-CSF Biosimilars is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for G-CSF and G-CSF Biosimilars. This report studies the global market size of G-CSF and G-CSF Biosimilars, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the G-CSF and G-CSF Biosimilars sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019. In global market, the following companies are covered: Pfizer Novartis Roche Merck & Co. Sanofi Johnson & Johnson Gilead Science GlaxoSmithKline AbbVie Amgen AstraZeneca Bayer Market Segment by Product Type Blood Disorders Oncology Diseases Chronic And Autoimmune Diseases Growth Hormone Deficiencies Market Segment by Application Human Growth Hormone Erythropoietin Monoclonal Antibodies Insulin Interferon Key Regions split in this report: breakdown data for each region. United States China European Union Rest of World (Japan, Korea, India and Southeast Asia) The study objectives are: To analyze and research the G-CSF and G-CSF Biosimilars status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast. To present the key G-CSF and G-CSF Biosimilars manufacturers, presenting the sales, revenue, market share, and recent development for key players. To split the breakdown data by regions, type, companies and applications To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. To identify significant trends, drivers, influence factors in global and regions To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market In this study, the years considered to estimate the market size of G-CSF and G-CSF Biosimilars are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025
Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Major Manufacturers Covered in This Report 1.3 Market Segment by Type 1.3.1 Global G-CSF and G-CSF Biosimilars Market Size Growth Rate by Type (2019-2025) 1.3.2 Blood Disorders 1.3.3 Oncology Diseases 1.3.4 Chronic And Autoimmune Diseases 1.3.5 Growth Hormone Deficiencies 1.4
Inquiry Before Buying

Request Sample

Share This Report

Our Clients

Payment Mode
Single User US $ 3280
Multi User US $4920
Corporate User US $6560
About this Report
Report ID 425621
Category
  • Pharmaceuticals and Healthcare
Published on 16-Sep
Number of Pages 117
Publisher Name QY Research
Editor Rating
★★★★★
★★★★★
(11)